As of 2025-12-22, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 10.9x | 8.4x |
| Forward P/E multiples | 12.9x - 15.5x | 14.6x |
| Fair Price | (23.99) - (20.72) | (21.69) |
| Upside | -757.2% - -667.7% | -694.2% |
| Date | EV/EBITDA |